<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04145245</url>
  </required_header>
  <id_info>
    <org_study_id>BSMMU/2019/3936</org_study_id>
    <nct_id>NCT04145245</nct_id>
  </id_info>
  <brief_title>A Randomized Controlled Trial to Assess the Effect of L-carnitine in Patients With Diabetic Peripheral Neuropathy to Relief Pain and Symptom Improvement</brief_title>
  <official_title>A Randomized Controlled Trial to Assess the Effect of L-carnitine in Patients With Diabetic Peripheral Neuropathy to Relief Pain and Symptom Improvement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic Peripheral Neuropathy (DPN) is a common complication of diabetes mellitus. The
      prevalence rate is approaching towards a peak throughout the world including Bangladesh. The
      current intervention used in peripheral neuropathy does not bring satisfactory result. Recent
      trial shows that L-carnitine is effective and safe in DPN. So it is expected that L-carnitine
      may produce better effect in compared to other medicine used previously for alleviation of
      DPN.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      : Diabetic peripheral neuropathy is one of the common complication of chronic diabetes
      mellitus, with a 30-50 % prevalence. Progressive development of pain, numbness in toes or
      feet and sensory motor disorders affects the patient's quality of life. The epidemic spread
      of the disease has raised concern among physicians and researchers. A variety of agents or
      medicines with potential effect have been studied to control development of peripheral
      neuropathy. The existing management are yet unsatisfactory. Recent studies have suggested
      that L-carnitine is potential to alleviate symptoms in patents with diabetic neuropathy.
      Previous trial also indicated the efficacy and safety of L-carnitine on diabetic neuropathy.
      This limitations have led to search for an effective and tolerable option by placebo
      controlled trial.The present study is an attempt to investigate the effects of carnitine on
      pain and symptom improvement of diabetic peripheral neuropathy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 17, 2018</start_date>
  <completion_date type="Anticipated">February 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Interventional Group- Patients with carnitine in addition to antidiabetic therapy Control Group- Patients with placebo and antidiabetic therapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>placebo controlled, double bind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>VAS score</measure>
    <time_frame>10 weeks</time_frame>
    <description>Alleviation of VAS Score of pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of neuropathic symptom</measure>
    <time_frame>10 weeks</time_frame>
    <description>Alleviation of NSS and NDS of diabetic neuropathy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Patient Compliance</condition>
  <arm_group>
    <arm_group_label>Intervention or group a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diabetic neuropathy patients with antidiabetic therapy in addition with l-carnitine supplementation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo or group b</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Diabetic neuropathy patients with antidiabetic treatment in addition with placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levocarnitine</intervention_name>
    <description>Levocarnitine syrup- oral supplementation about 1500 mg/day for 10 weeks</description>
    <arm_group_label>Intervention or group a</arm_group_label>
    <arm_group_label>Placebo or group b</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        i. Clinically diagnosed diabetic patients who had been on stable antidiabetic therapy for 1
        year ii.Age: 18 years to 70 years iii. Patients HbA1c level &lt;10

        Exclusion Criteria:

        i. Patient who are suffering from other causes of peripheral neuropathy for example
        chemotherapy and HIV patient, rheumatoid arthritis, SLE, alcololism, vitamin B12 deficiency
        etc ii. Lactating and pregnant women iii. Patients taking anticonvulsants, antidepressants,
        opoioids and other neuropathic pain medication agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Farhana Haque, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Resident, phase-B</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Farhana Haque, MBBS</last_name>
    <phone>01734342464</phone>
    <email>farhanahaque857@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zesmin Dewan, PHD</last_name>
    <phone>01712533169</phone>
    <email>jfdewan@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pharmacology department,BSMMU.</name>
      <address>
        <city>Dhaka</city>
        <state>Dhaka,Sahbagh</state>
        <zip>02</zip>
        <country>Bangladesh</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farhana Haque, MBBS</last_name>
      <phone>01734342464</phone>
      <email>farhanahaque857@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Zesmin Dewan, PHD</last_name>
      <phone>01712533169</phone>
      <email>jfdewan@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Bangladesh</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 29, 2019</study_first_submitted>
  <study_first_submitted_qc>October 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2019</study_first_posted>
  <last_update_submitted>October 29, 2019</last_update_submitted>
  <last_update_submitted_qc>October 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</investigator_affiliation>
    <investigator_full_name>Farhana Haque</investigator_full_name>
    <investigator_title>Farhana Haque</investigator_title>
  </responsible_party>
  <keyword>DPN, Levocarnitine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

